Why Is Amkor Stock Up So Much?
Semiconductor packaging and testing major Amkor (NASDAQ:AMKR) has started 2026…
Buy
55
PRE Quote, Financials, Valuation and Earnings
Last price:
$15.74
Seasonality move
:
-28.31%
Day range:
$15.29 - $16.96
52-week range:
$3.09 - $18.48
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
3.02x
P/B ratio:
1.62x
Volume:
271.5K
Avg. volume:
154.5K
1-year change:
190.28%
Market cap:
$261.3M
Revenue:
$30.6M
EPS (TTM):
-$3.65
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
PRE
Prenetics Global Ltd.
|
$45.9M | -- | 265.18% | -- | $26.00 |
|
HCM
HUTCHMED (China) Ltd.
|
-- | -- | -- | -- | $22.38 |
|
HKPD
Cellyan Biotechnology Ltd.
|
-- | -- | -- | -- | -- |
|
RGC
Regencell Bioscience Holdings Ltd.
|
-- | -- | -- | -- | -- |
|
SBHMY
Sino Biopharmaceutical Ltd.
|
-- | -- | -- | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
PRE
Prenetics Global Ltd.
|
$15.53 | $26.00 | $261.3M | -- | $0.00 | 0% | 3.02x |
|
HCM
HUTCHMED (China) Ltd.
|
$14.72 | $22.38 | $2.5B | 4.92x | $0.00 | 0% | 4.25x |
|
HKPD
Cellyan Biotechnology Ltd.
|
$0.78 | -- | $8.5M | 8.18x | $0.00 | 0% | 0.75x |
|
RGC
Regencell Bioscience Holdings Ltd.
|
$45.79 | -- | $22.6B | -- | $0.00 | 0% | -- |
|
SBHMY
Sino Biopharmaceutical Ltd.
|
$18.22 | -- | $16.3B | 31.84x | $0.13 | 1.26% | 3.87x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
PRE
Prenetics Global Ltd.
|
1.29% | 5.284 | 1.18% | 1.01x |
|
HCM
HUTCHMED (China) Ltd.
|
7.07% | 0.158 | -- | 4.41x |
|
HKPD
Cellyan Biotechnology Ltd.
|
-- | 0.000 | -- | -- |
|
RGC
Regencell Bioscience Holdings Ltd.
|
-- | 18.151 | -- | -- |
|
SBHMY
Sino Biopharmaceutical Ltd.
|
23.1% | -0.664 | -- | 1.14x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
PRE
Prenetics Global Ltd.
|
$14M | -$6.6M | -26.04% | -26.74% | -27.85% | -- |
|
HCM
HUTCHMED (China) Ltd.
|
-- | -- | 46.32% | 50.64% | -- | -- |
|
HKPD
Cellyan Biotechnology Ltd.
|
-- | -- | -- | -- | -- | -- |
|
RGC
Regencell Bioscience Holdings Ltd.
|
-- | -- | -- | -- | -- | -- |
|
SBHMY
Sino Biopharmaceutical Ltd.
|
-- | -- | 6.83% | 8.57% | -- | -- |
Prenetics Global Ltd. vs. Competitors
-
Which has Higher Returns PRE or HCM?
HUTCHMED (China) Ltd. has a net margin of -28.82% compared to Prenetics Global Ltd.'s net margin of --. Prenetics Global Ltd.'s return on equity of -26.74% beat HUTCHMED (China) Ltd.'s return on equity of 50.64%.
Company Gross Margin Earnings Per Share Invested Capital PREPrenetics Global Ltd.59.54% -$0.53 $163.3M HCMHUTCHMED (China) Ltd.-- -- $1.3B -
What do Analysts Say About PRE or HCM?
Prenetics Global Ltd. has a consensus price target of $26.00, signalling upside risk potential of 99.61%. On the other hand HUTCHMED (China) Ltd. has an analysts' consensus of $22.38 which suggests that it could grow by 52.07%. Given that Prenetics Global Ltd. has higher upside potential than HUTCHMED (China) Ltd., analysts believe Prenetics Global Ltd. is more attractive than HUTCHMED (China) Ltd..
Company Buy Ratings Hold Ratings Sell Ratings PREPrenetics Global Ltd.1 0 0 HCMHUTCHMED (China) Ltd.9 2 1 -
Is PRE or HCM More Risky?
Prenetics Global Ltd. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison HUTCHMED (China) Ltd. has a beta of 0.418, suggesting its less volatile than the S&P 500 by 58.206%.
-
Which is a Better Dividend Stock PRE or HCM?
Prenetics Global Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. HUTCHMED (China) Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Prenetics Global Ltd. pays -- of its earnings as a dividend. HUTCHMED (China) Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PRE or HCM?
Prenetics Global Ltd. quarterly revenues are $23.6M, which are larger than HUTCHMED (China) Ltd. quarterly revenues of --. Prenetics Global Ltd.'s net income of -$6.8M is higher than HUTCHMED (China) Ltd.'s net income of --. Notably, Prenetics Global Ltd.'s price-to-earnings ratio is -- while HUTCHMED (China) Ltd.'s PE ratio is 4.92x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Prenetics Global Ltd. is 3.02x versus 4.25x for HUTCHMED (China) Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PREPrenetics Global Ltd.3.02x -- $23.6M -$6.8M HCMHUTCHMED (China) Ltd.4.25x 4.92x -- --
-
Which has Higher Returns PRE or HKPD?
Cellyan Biotechnology Ltd. has a net margin of -28.82% compared to Prenetics Global Ltd.'s net margin of --. Prenetics Global Ltd.'s return on equity of -26.74% beat Cellyan Biotechnology Ltd.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital PREPrenetics Global Ltd.59.54% -$0.53 $163.3M HKPDCellyan Biotechnology Ltd.-- -- -- -
What do Analysts Say About PRE or HKPD?
Prenetics Global Ltd. has a consensus price target of $26.00, signalling upside risk potential of 99.61%. On the other hand Cellyan Biotechnology Ltd. has an analysts' consensus of -- which suggests that it could fall by --. Given that Prenetics Global Ltd. has higher upside potential than Cellyan Biotechnology Ltd., analysts believe Prenetics Global Ltd. is more attractive than Cellyan Biotechnology Ltd..
Company Buy Ratings Hold Ratings Sell Ratings PREPrenetics Global Ltd.1 0 0 HKPDCellyan Biotechnology Ltd.0 0 0 -
Is PRE or HKPD More Risky?
Prenetics Global Ltd. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Cellyan Biotechnology Ltd. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock PRE or HKPD?
Prenetics Global Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cellyan Biotechnology Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Prenetics Global Ltd. pays -- of its earnings as a dividend. Cellyan Biotechnology Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PRE or HKPD?
Prenetics Global Ltd. quarterly revenues are $23.6M, which are larger than Cellyan Biotechnology Ltd. quarterly revenues of --. Prenetics Global Ltd.'s net income of -$6.8M is higher than Cellyan Biotechnology Ltd.'s net income of --. Notably, Prenetics Global Ltd.'s price-to-earnings ratio is -- while Cellyan Biotechnology Ltd.'s PE ratio is 8.18x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Prenetics Global Ltd. is 3.02x versus 0.75x for Cellyan Biotechnology Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PREPrenetics Global Ltd.3.02x -- $23.6M -$6.8M HKPDCellyan Biotechnology Ltd.0.75x 8.18x -- --
-
Which has Higher Returns PRE or RGC?
Regencell Bioscience Holdings Ltd. has a net margin of -28.82% compared to Prenetics Global Ltd.'s net margin of --. Prenetics Global Ltd.'s return on equity of -26.74% beat Regencell Bioscience Holdings Ltd.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital PREPrenetics Global Ltd.59.54% -$0.53 $163.3M RGCRegencell Bioscience Holdings Ltd.-- -- -- -
What do Analysts Say About PRE or RGC?
Prenetics Global Ltd. has a consensus price target of $26.00, signalling upside risk potential of 99.61%. On the other hand Regencell Bioscience Holdings Ltd. has an analysts' consensus of -- which suggests that it could fall by --. Given that Prenetics Global Ltd. has higher upside potential than Regencell Bioscience Holdings Ltd., analysts believe Prenetics Global Ltd. is more attractive than Regencell Bioscience Holdings Ltd..
Company Buy Ratings Hold Ratings Sell Ratings PREPrenetics Global Ltd.1 0 0 RGCRegencell Bioscience Holdings Ltd.0 0 0 -
Is PRE or RGC More Risky?
Prenetics Global Ltd. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Regencell Bioscience Holdings Ltd. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock PRE or RGC?
Prenetics Global Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Regencell Bioscience Holdings Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Prenetics Global Ltd. pays -- of its earnings as a dividend. Regencell Bioscience Holdings Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PRE or RGC?
Prenetics Global Ltd. quarterly revenues are $23.6M, which are larger than Regencell Bioscience Holdings Ltd. quarterly revenues of --. Prenetics Global Ltd.'s net income of -$6.8M is higher than Regencell Bioscience Holdings Ltd.'s net income of --. Notably, Prenetics Global Ltd.'s price-to-earnings ratio is -- while Regencell Bioscience Holdings Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Prenetics Global Ltd. is 3.02x versus -- for Regencell Bioscience Holdings Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PREPrenetics Global Ltd.3.02x -- $23.6M -$6.8M RGCRegencell Bioscience Holdings Ltd.-- -- -- --
-
Which has Higher Returns PRE or SBHMY?
Sino Biopharmaceutical Ltd. has a net margin of -28.82% compared to Prenetics Global Ltd.'s net margin of --. Prenetics Global Ltd.'s return on equity of -26.74% beat Sino Biopharmaceutical Ltd.'s return on equity of 8.57%.
Company Gross Margin Earnings Per Share Invested Capital PREPrenetics Global Ltd.59.54% -$0.53 $163.3M SBHMYSino Biopharmaceutical Ltd.-- -- $7.2B -
What do Analysts Say About PRE or SBHMY?
Prenetics Global Ltd. has a consensus price target of $26.00, signalling upside risk potential of 99.61%. On the other hand Sino Biopharmaceutical Ltd. has an analysts' consensus of -- which suggests that it could fall by --. Given that Prenetics Global Ltd. has higher upside potential than Sino Biopharmaceutical Ltd., analysts believe Prenetics Global Ltd. is more attractive than Sino Biopharmaceutical Ltd..
Company Buy Ratings Hold Ratings Sell Ratings PREPrenetics Global Ltd.1 0 0 SBHMYSino Biopharmaceutical Ltd.0 0 0 -
Is PRE or SBHMY More Risky?
Prenetics Global Ltd. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Sino Biopharmaceutical Ltd. has a beta of 0.590, suggesting its less volatile than the S&P 500 by 40.969%.
-
Which is a Better Dividend Stock PRE or SBHMY?
Prenetics Global Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Sino Biopharmaceutical Ltd. offers a yield of 1.26% to investors and pays a quarterly dividend of $0.13 per share. Prenetics Global Ltd. pays -- of its earnings as a dividend. Sino Biopharmaceutical Ltd. pays out 55.99% of its earnings as a dividend. Sino Biopharmaceutical Ltd.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios PRE or SBHMY?
Prenetics Global Ltd. quarterly revenues are $23.6M, which are larger than Sino Biopharmaceutical Ltd. quarterly revenues of --. Prenetics Global Ltd.'s net income of -$6.8M is higher than Sino Biopharmaceutical Ltd.'s net income of --. Notably, Prenetics Global Ltd.'s price-to-earnings ratio is -- while Sino Biopharmaceutical Ltd.'s PE ratio is 31.84x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Prenetics Global Ltd. is 3.02x versus 3.87x for Sino Biopharmaceutical Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PREPrenetics Global Ltd.3.02x -- $23.6M -$6.8M SBHMYSino Biopharmaceutical Ltd.3.87x 31.84x -- --
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Shopify Stock a Good Buy Now?
eCommerce technology platform Shopify (NASDAQ:SHOP) delivered impressive returns in 2025…
Will The Magnificent 7 Stocks Go Up This Year?
2025 was another banner year for the Magnificent Seven stocks,…
Stock Ideas
Buy
52
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 63x
Buy
65
Is GOOG Stock a Buy?
Market Cap: $4T
P/E Ratio: 41x
Buy
51
Is GOOGL Stock a Buy?
Market Cap: $4T
P/E Ratio: 41x
Alerts
Buy
100
ATGL alert for Jan 10
Alpha Technology Group Ltd. [ATGL] is up 47.05% over the past day.
Buy
71
NAIL alert for Jan 10
Direxion Daily Homebuilders & Supplies Bull 3X Shs [NAIL] is up 18.52% over the past day.
Buy
54
LGIH alert for Jan 10
LGI Homes, Inc. [LGIH] is up 13.81% over the past day.
